Accelerating Pneumococcal Conjugate Vaccine introductions in Indonesia: key learnings from 2017 to 2022. [PDF]
Athiyaman A+6 more
europepmc +1 more source
Long-term impact of 10-valent pneumococcal conjugate vaccine among children <5 years, Uganda, 2014-2021. [PDF]
Wanyana MW+7 more
europepmc +1 more source
Similar Antibody Concentrations in Filipino Infants at Age 9 Months, after 1 or 3 Doses of an Adjuvanted, 11‐Valent Pneumococcal Diphtheria/Tetanus–Conjugated Vaccine: A Randomized Controlled Trial [PDF]
Marilla Lucero+5 more
openalex +1 more source
Cost-effectiveness analysis of the 13-valent pneumococcal conjugate vaccine administered to children under 5 years of age in the Republic of Moldova. [PDF]
Balanuta AM+4 more
europepmc +1 more source
Antibody Response to a Seven-Valent Pneumococcal Conjugated Vaccine in Patients with Ataxia-Telangiectasia [PDF]
Özden Sanal+6 more
openalex +1 more source
Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit. [PDF]
Perdrizet J+6 more
europepmc +1 more source
What can children gain from pneumococcal conjugate vaccines? [PDF]
Heikki Peltola+2 more
openalex +1 more source
Correction to: Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. [PDF]
europepmc +1 more source